G-CSF-induced remission in two cases of acute myeloid leukemia.
We report on two elderly patients with newly diagnosed acute myeloid leukemia (AML) who were treated in palliative intention because of comorbidities and intermediate or poor risk cytogenetics. Both received G-CSF to reduce the risk of infection related to neutropenia. Interestingly, one patient achieved a full hematological remission and the other a peripheral remission with dramatic reduction of the bone marrow blast count. Although a direct therapeutic effect of myeloid growth factors seems to be unusual in AML, the use of G-CSF or GM-CSF may be recommended in patients such as elderly patients who are not suited for intensive chemotherapy.
Benz
Rudolf
R
Department of Hematology, University Hospital Zurich, Rämistrasse 100, 8091 Zürich, Switzerland. rudolf.benz@usz.ch
Goede
Jeroen S
JS
Parlier
Valérie
V
Mühlematter
Dominique
D
Jotterand
Martine
M
Fehr
Jörg
J
D000368:Aged; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction
D016179:Granulocyte Colony-Stimulating Factor